HC Wainwright Has Optimistic Outlook of Kamada Q3 Earnings

Kamada Ltd. (NASDAQ:KMDA) – Analysts at HC Wainwright upped their Q3 2026 earnings per share estimates for Kamada in a report released on Friday, August 14th. HC Wainwright analyst A. Fein now expects that the biotechnology company will earn $0.16 per share for the quarter, up from their prior forecast of $0.13. The consensus estimate for Kamada’s current full-year earnings is $0.45 per share. HC Wainwright also issued estimates for Kamada’s Q4 2026 earnings at $0.13 EPS, FY2026 earnings at $0.52 EPS and FY2030 earnings at $1.11 EPS.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.05. The company had revenue of $54.92 million during the quarter, compared to analysts’ expectations of $50.84 million. Kamada had a return on equity of 8.37% and a net margin of 11.60%.

KMDA has been the topic of a number of other research reports. Benchmark reaffirmed a “buy” rating on shares of Kamada in a research report on Tuesday, July 21st. Wall Street Zen upgraded Kamada from a “hold” rating to a “strong-buy” rating in a report on Saturday. Weiss Ratings downgraded shares of Kamada from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 25th. Finally, William Blair set a $15.00 target price on shares of Kamada in a research report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, Kamada currently has a consensus rating of “Buy” and a consensus price target of $13.00.

Kamada Stock Performance

Kamada stock opened at $7.76 on Tuesday. The firm has a market cap of $446.28 million, a price-to-earnings ratio of 20.42, a PEG ratio of 0.67 and a beta of 0.86. Kamada has a 52-week low of $6.50 and a 52-week high of $9.35. The firm has a 50 day moving average price of $7.23 and a two-hundred day moving average price of $7.95.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of KMDA. Aristides Capital LLC raised its position in Kamada by 4.5% during the first quarter. Aristides Capital LLC now owns 34,491 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 1,476 shares in the last quarter. NewEdge Advisors LLC increased its holdings in Kamada by 9.2% in the 4th quarter. NewEdge Advisors LLC now owns 57,538 shares of the biotechnology company’s stock worth $406,000 after acquiring an additional 4,870 shares in the last quarter. XTX Topco Ltd bought a new stake in Kamada during the 4th quarter valued at approximately $103,000. Quadrature Capital Ltd boosted its holdings in shares of Kamada by 53.5% during the 4th quarter. Quadrature Capital Ltd now owns 21,889 shares of the biotechnology company’s stock valued at $155,000 after purchasing an additional 7,627 shares during the last quarter. Finally, Man Group plc boosted its stake in Kamada by 19.9% during the fourth quarter. Man Group plc now owns 34,294 shares of the biotechnology company’s stock valued at $242,000 after buying an additional 5,684 shares during the last quarter. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Kamada Cuts Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, September 17th. Shareholders of record on Thursday, August 27th will be given a dividend of $0.17 per share. The ex-dividend date is Thursday, August 27th. This represents a dividend yield of 219.0%. Kamada’s dividend payout ratio is currently 50.00%.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.